Analyst consensus rating
Arbutus Biopharma Corporation Analyst Consensus Rating
ABUS analyst consensus rating, coverage count and price target evidence.
Direct answer
Arbutus Biopharma Corporation's consensus rating is Strong Buy.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $5.55.
Forecast evidence checked August 11, 2026.
Get free Arbutus Biopharma Corporation email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.67
- Average price target
- $5.55
- High price target
- $5.55
- Low price target
- $5.55
- Target upside
- +18.8%
- Consensus rating
- Strong Buy
- Analysts
- 1
- Evidence date
- August 11, 2026
- Valid through
- August 18, 2026